Advanced

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Bergenfelz, Caroline LU ; Roxå, Anna ; Mehmeti, Meliha LU ; Leandersson, Karin LU and Larsson, Anna Maria LU (2020) In Cancer Immunology, Immunotherapy
Abstract

The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in... (More)

The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
epub
subject
keywords
Breast cancer, Estrogen receptor, Metastasis, Mo-MDSCs, Survival
in
Cancer Immunology, Immunotherapy
publisher
Springer
external identifiers
  • pmid:31925475
  • scopus:85077708211
ISSN
0340-7004
DOI
10.1007/s00262-019-02472-z
language
English
LU publication?
yes
id
6a1ee857-dd97-4869-a0fa-8f6d69b86aae
date added to LUP
2020-01-28 08:55:56
date last changed
2020-10-20 05:00:46
@article{6a1ee857-dd97-4869-a0fa-8f6d69b86aae,
  abstract     = {<p>The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.</p>},
  author       = {Bergenfelz, Caroline and Roxå, Anna and Mehmeti, Meliha and Leandersson, Karin and Larsson, Anna Maria},
  issn         = {0340-7004},
  language     = {eng},
  month        = {01},
  publisher    = {Springer},
  series       = {Cancer Immunology, Immunotherapy},
  title        = {Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer},
  url          = {http://dx.doi.org/10.1007/s00262-019-02472-z},
  doi          = {10.1007/s00262-019-02472-z},
  year         = {2020},
}